http://www.aism.it/index.aspx?codpage=n ... 9_09_ccsvi
my notes are in parenthesis-
Cerebrospinal chronic venous insufficiency (CCSVI) and multiple sclerosis
The cause or rather the causes of MS are still largely unknown, but research has made great strides to clarify the way the disease works and thus make possible an early diagnosis and treatment to enable people with MS to maintain a good quality of life.
Identify the causative factor or event that triggers the first episode of disease and understanding whether there are risk factors beyond genetics predispose to the development of MS are among the goals of scientific research, crucial to identify new therapeutic approaches and intervene at the level of prevention.
In this area you place the line of research conducted by Professor Paolo Zamboni, director of the Vascular Diseases Center, University of Ferrara. At a scientific conference, organized by the Foundation in Bologna Hilarescere held on 8 September 2009, Professor Zamboni presented the results of a study on "Venous Function and Multiple Sclerosis" which were taken from various newspapers and websites.
This is already the subject of research publications since 2006 such as the article published in the scientific journal Journal of neurology, neurosurgery and psychiatry, "cerebrospinal Chronic venous insufficiency in patients with multiple sclerosis. P. Zamboni, R. Galeotti, E. Menegatti, AMMalagoni, G. Tacconi, S. Dall 'Ara, I. Bartolomei, F. Salvi, 2009, April 80 (4): 392-399) and the review published at the time only online in the Journal of Cerebral Blood Flow & Metabolism (2009, September), "Anomalous venous blood flow and iron deposition in multiple sclerosis" Ajay V. Singh and Paolo Zamboni.
The paper published in April this year involved 65 people with clinically definite MS and 235 controls that include both healthy subjects and those suffering from other neurological diseases other than MS. The study was conducted with ultrasonic methods and parameters were evaluated to assess the functionality of the internal jugular veins, vertebral veins and deep cerebral veins.
The study said a possible correlation between the cerebrospinal chronic venous insufficiency (Chronic cerebrospinal venous insufficiency, CCSVI) that affects the veins of the brain, and the possibility that the sufferer may develop multiple sclerosis. The authors conclude work on the assumption that a venous malformation of congenital origin associated with MS may be plausible. Additional data were also reported in two posters presented during the last Congress ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) held in Germany, 9 to 12 September 2009.
(this isn't what the published paper said. It showed CCSVI in 100% of MS patients. Nothing was mentioned re: congenital connections and venous malformations- that was from Dr. BB Lee. Did they read the research?)
To confirm this hypothesis, the authors argue that further and further study in order to understand the possible role of chronic venous insufficiency on inflammation and neurodegenerative disease.
The president of the Foundation Hilarescere Professor Fabio Roversi-Monaco, who organized the conference held in Bologna on 8 September, said: "It takes a very strict, so we invited the Congress also some critical voices. The risk that we run is to deceive patients and families. We go there with feet of lead. "
In this connection Professor Marco Salvetti, University "La Sapienza", Centro Experimental therapies and neurological (centers) in Rome, a member of the Scientific Committee AISM and IMF, who has personally participated in the conference said: "The data presented affects both their significance because of the difficulty of reconciling them with what we already know about MS: oligoclonal bands, remitting course, changes in prevalence in different populations, etc.. The next important step would be to find a point of contact between these observations and the results already established in the field of epidemiology and immunogenetics. "
(Here will be their argument...making the new peg fit in the old hole....with a complete disregard for the scientific discovery. And we've talked about all of these arguments on here for months...oligo bands in stroke sufferers CSF due to hypoxia, remitting in terms of endothelial disruption, congenital connections, etc.)
Professor Gianluigi Mancardi, Director of Neurology, University of Genoa and President of the Scientific Committee dell'AISM, said that "Given the high individual variability of the venous circulation is necessary for the data, however, interesting colleagues of Ferrara, are first confirmed by other laboratories with established expertise on the study of venous circulation. This is however not clear whether these abnormalities are primary or secondary to other diseases possibly only, probably inflammatory, central nervous system. "
Professor Jerry Wolinsky School of Medicine, University of Texas at Houston in summarizing the scientific presentations at the recent congress ECTRIMS, where were presented two posters on the theme of Professor Zamboni, stressed that "Even 35 years ago it was valued this aspect pathology in MS will continue research and while we must have a clinical approach to very careful and do extensive research and correct because we do not know whether, as a result of this knowledge, there could be a treatment, and if so, should be for a few or many and we should not treat too many useless people. "
(Again, doctors will say..,we've already looked at the vascular connection, we tried blood thinners 35 years ago, it didn't work. BUT No one has looked at the venous system in terms of neurological disease EVER! It hasn't been possible before. This argument is DOA.)
In conclusion, Professor Mario Alberto Battaglia, president of the Italian Multiple Sclerosis Foundation, said: "This research comes in addition to others that aim to identify possible risk factors associated with the development of MS. The real problem is expected to be clear whether the venous abnormalities identified in this study play a role in the pathogenesis of the disease or are a factor and is not associated with clinical trials to assess the possible consequences (including long-term) corrective action. These additional assessments should be carried out bearing in mind that in 70% of the placebo has a positive effect on the disease and that both the natural history of developments in the SM treated with current therapies, often show improvement in the manifestations of the disease and the quality of life. "
As always, the Italian Multiple Sclerosis Society recommends that people with MS to follow the therapy for each of their officers who have already proved effective and consult their doctor to choose the best course of treatment.
I'm not surprised, but still, disappointed. GiCi is right, this is going to take years of studies to be accepted by the mainstream. Sorry, folks.